Hypoxic antiblastic stop-flow perfusion: clinical outcome and pharmacokinetic findings.
Stop-flow perfusion (SFP) is a recently implemented locoregional treatment based on the vascular isolation of the tumor bearing body district through a radiointerventistic technique. SFP is currently under investigation as a palliative therapeutic option for patients with locally advanced tumors. This paper reports on the results of our prospective study of limb and pelvic SFP. Thirty-seven patients were treated with SFP. No postoperative deaths occurred. Locoregional and systemic toxicity were observed after 22 and 31 treatments, respectively; complete and partial response after 3 (6%) and 24 (51%) SFPs, respectively. The pharmacokinetic study showed that pelvic SFP was associated with a leakage rate higher than femoral SFP (38% vs 28%). In conclusion, SFP is a feasible procedure. Toxicity and tumor response rates strictly depend upon drug leakage control.
Miotto
D
D
Department of Oncological and Surgical Sciences, University of Padova, Italy. pl.pilati@unipd.it
Miotto
D
D
Bertolo
S
S
Minante
M
M
Darisi
T
T
Mocellin
S
S
Casara
D
D
Ori
C
C
Foletto
M
M
Rossi
C R
CR
Lise
M
M
Nitti
D
D
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000493:pharmacokinetics*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011446:Prospective Studies
D000970:Antineoplastic Agents; D008558:Melphalan